The coronavirus outbreak, though the majority of cases have been in China, has affected many aspects of global life, especially businesses and travel. The virus can be easily spread from person to person by close contact and respiratory droplets from an infected person being inhaled. But while coronavirus has occupied the spotlight, there are still other infectious diseases being tested in China. An analysis can be completed for those other infectious disease clinical trials by using the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. In this article, GlobalData presents such an analysis.

When looking at infectious disease clinical trials in China, completed trials outnumber trials of any other status. Completed clinical trials made up 56.9% of all infectious disease trials in China, with “ongoing, recruiting” following with 18.3%, and “planned” with 13.3%. Suspended/withdrawn/terminated (S/W/T), “ongoing, not recruiting,” and “ongoing, recruiting by invitation” were the three least common, with no more than 6.7% each. This can be seen in Figure 1.

Phase I was the most common current infectious disease clinical trial phase in China with 32.9%, followed by Phase IV (26.9%), Phase II (26.4%), and Phase III with 13.7%. (A small number of Phase 0, Phase I / II, Phase II/III, and Phase III / IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively).

Lastly, when looking at these trials by trial site spread, the majority of the infectious disease trials in China are single country; fewer are multinational. Single country trials outnumbered multinational country clinical trials with 87%.